Ryvu Therapeutics (RVU) Q4 2024 earnings summary

Executive summary

• Operating revenue rose to PLN 102.0M in 2024, up from PLN 68.0M in 2023, driven by increased sales, R&D project revenues, and subsidies, notably from BioNTech and Exelixis collaborations.

• Net loss widened to PLN 111.4M from PLN 92.1M year-over-year, reflecting higher R&D and clinical development spending.

• Cash and equivalents at year-end were PLN 160.1M, bolstered by EIB financing; total assets stood at PLN 378.8M.

• Strategic reorganization in early 2025, including a 30% workforce reduction and pipeline prioritization, extends cash runway to H2 2026.

Financial highlights

• Sales revenue increased to PLN 56.0M (2023: PLN 28.5M); R&D project revenue reached PLN 22.0M (2023: PLN 18.4M).

• Operating expenses rose to PLN 224.1M (2023: PLN 168.9M), mainly due to R&D investments.

• EBITDA was negative PLN 111.6M; net cash outflow from operations was PLN 129.5M.

• No dividend declared or paid.

Outlook and guidance

• Cash runway extended to H2 2026 following cost reductions and pipeline adjustments.

• Focus on advancing RVU120 clinical program and early pipeline to key data points in 2025–2026.

• Anticipates reduced revenue from BioNTech collaboration starting Q2 2025 due to STING program termination.